Bio-Path Holdings, Inc. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2013
January 01, 2014 at 08:02 am EST
Share
Bio-Path Holdings, Inc. announced financial results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported net operating loss was $1.39 million, compared to a net operating loss of $840,489 for the same quarter ended September 30, 2012.
Net loss for the nine months ended September 30, 2013 was $2.48 million, or $0.04 loss per share, compared to a net loss of $2.15 million, or $0.04 loss per share, for the same period ended September 30, 2012. Net operating loss for the nine months ended September 30, 2013 was $2.48 million, compared to a net operating loss of $2.15 million for the same period ended September 30, 2012.
Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.
BIO-PATH HOLDINGS, INC. 
